董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Scheller | 男 | Chair of the Board, Director | 67 | 2.00万美元 | 未持股 | 2021-07-31 |
| Sharon Tetlow | 女 | Director | 61 | 未披露 | 未持股 | 2021-07-31 |
| Shaan C. Gandhi | 男 | Director | 35 | 未披露 | 未持股 | 2021-07-31 |
| Jake Simson | 男 | Director | 35 | 未披露 | 未持股 | 2021-07-31 |
| Jim Scopa | 男 | Director | 62 | 0.45万美元 | 未持股 | 2021-07-31 |
| Stephen Zachary | 男 | Director | 39 | 未披露 | 未持股 | 2021-07-31 |
| J. Kevin Judice | 男 | Founder, Chief Executive Officer and Director | 58 | 63.65万美元 | 未持股 | 2021-07-31 |
| Sharon Tetlow | 女 | Director | 61 | 0.45万美元 | 未持股 | 2021-07-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| J. Kevin Judice | 男 | Founder, Chief Executive Officer and Director | 58 | 63.65万美元 | 未持股 | 2021-07-31 |
| John Jacobsen | 男 | Chief Scientific Officer | 53 | 71.48万美元 | 未持股 | 2021-07-31 |
| Timothy Lu | 男 | Chief Medical Officer | 47 | 未披露 | 未持股 | 2021-07-31 |
| Scott Robertson | 男 | Chief Business and Financial Officer | 42 | 60.40万美元 | 未持股 | 2021-07-31 |
董事简历
中英对照 | 中文 | 英文- Richard Scheller
-
Richard Scheller，自2019年6月起担任Maze Therapeutics，Inc.董事会成员。Scheller博士目前担任生物技术公司BridgeBio Pharma Inc.的研发主席，自2019年1月起担任该职务，并于2018年1月至2021年2月担任该公司董事会成员。他此前曾于2015年至2019年担任个人基因组学公司23andMe，Inc.的Therapeutics负责人和首席科学官，并自2019年初起担任该公司董事会成员。他还担任Alector, Inc.的董事会成员。从2001年到2014年，Scheller博士在生物技术公司基因泰克工作了14年，在那里他担任研究和早期开发执行副总裁。1982年至2001年，谢勒博士在斯坦福大学任教，担任生物科学系和分子与细胞生理学系教授，并担任斯坦福大学医学中心霍华德·休斯医学研究所的研究员。自2004年以来，Scheller博士一直担任加州大学旧金山分校生物化学和生物物理系的兼职教授。他在职业生涯中发表了200多篇初级研究论文。Scheller博士获得Kavli神经科学奖（2010年），是美国国家科学院和美国国家医学研究院的成员。Scheller博士获得了加州理工学院的化学博士学位和威斯康星大学麦迪逊分校的生物化学学士学位。
Richard Scheller,has served as a member of Board of Directors and Scientific Advisory Board ("SAB") since October 2018 and has served as co-chair of Strategic Portfolio Advice and Review Committee ("SPARC") since December 2019. Dr. Scheller has served as the Chairman of Research and Development at BridgeBio Pharma LLC, a publicly traded biotechnology company, since January 2019 and as a member of its board of directors from 2018 to 2023. In addition, Dr. Scheller serves on the board of directors at Maze Therapeutics, Aarvik Therapeutics, Trace Neuroscience, Xaira, and GondolaBio, and on the board of trustees at Caltech and the board of the Corporation of the Fine Arts Museums of San Francisco. He previously served on the board of directors of Xenon Pharmaceuticals from 2015 to 2020, ORIC Pharmaceuticals from 2015 to 2021, and as chairman of the board of directors of DICE Therapeutics from 2015 to 2023. From 2015 to 2019, Dr. Scheller was Head of Therapeutics and Chief Scientific Officer at 23andMe Holding Co. At Genentech from 2001 to 2014, he was Executive Vice President of Research and Early Development and served on the executive committees of Roche and Genentech focusing on research strategy, drug discovery, business development and early drug development activities. From 1982 to 2001, Dr. Scheller was a professor at Stanford in the Department of Biological Sciences and the Department of Molecular and Cellular Physiology and was an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center. Since 2004, Dr. Scheller has served as an adjunct professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco. Dr. Scheller's research elucidating the molecular machinery and regulatory mechanism that underly neurotransmitter release earned him the 2013 Albert Lasker Basic Medical Research Award, the 2010 Kavli Prize in Neuroscience, and the 1997 U.S. National Academy of Sciences Award in Molecular Biology. He is a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences, and a member of the National Academy of Medicine. Dr. Scheller holds a Ph.D. in Chemistry from the California Institute of Technology and B.Sc. in Biochemistry from the University of Wisconsin-Madison. - Richard Scheller，自2019年6月起担任Maze Therapeutics，Inc.董事会成员。Scheller博士目前担任生物技术公司BridgeBio Pharma Inc.的研发主席，自2019年1月起担任该职务，并于2018年1月至2021年2月担任该公司董事会成员。他此前曾于2015年至2019年担任个人基因组学公司23andMe，Inc.的Therapeutics负责人和首席科学官，并自2019年初起担任该公司董事会成员。他还担任Alector, Inc.的董事会成员。从2001年到2014年，Scheller博士在生物技术公司基因泰克工作了14年，在那里他担任研究和早期开发执行副总裁。1982年至2001年，谢勒博士在斯坦福大学任教，担任生物科学系和分子与细胞生理学系教授，并担任斯坦福大学医学中心霍华德·休斯医学研究所的研究员。自2004年以来，Scheller博士一直担任加州大学旧金山分校生物化学和生物物理系的兼职教授。他在职业生涯中发表了200多篇初级研究论文。Scheller博士获得Kavli神经科学奖（2010年），是美国国家科学院和美国国家医学研究院的成员。Scheller博士获得了加州理工学院的化学博士学位和威斯康星大学麦迪逊分校的生物化学学士学位。
- Richard Scheller,has served as a member of Board of Directors and Scientific Advisory Board ("SAB") since October 2018 and has served as co-chair of Strategic Portfolio Advice and Review Committee ("SPARC") since December 2019. Dr. Scheller has served as the Chairman of Research and Development at BridgeBio Pharma LLC, a publicly traded biotechnology company, since January 2019 and as a member of its board of directors from 2018 to 2023. In addition, Dr. Scheller serves on the board of directors at Maze Therapeutics, Aarvik Therapeutics, Trace Neuroscience, Xaira, and GondolaBio, and on the board of trustees at Caltech and the board of the Corporation of the Fine Arts Museums of San Francisco. He previously served on the board of directors of Xenon Pharmaceuticals from 2015 to 2020, ORIC Pharmaceuticals from 2015 to 2021, and as chairman of the board of directors of DICE Therapeutics from 2015 to 2023. From 2015 to 2019, Dr. Scheller was Head of Therapeutics and Chief Scientific Officer at 23andMe Holding Co. At Genentech from 2001 to 2014, he was Executive Vice President of Research and Early Development and served on the executive committees of Roche and Genentech focusing on research strategy, drug discovery, business development and early drug development activities. From 1982 to 2001, Dr. Scheller was a professor at Stanford in the Department of Biological Sciences and the Department of Molecular and Cellular Physiology and was an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center. Since 2004, Dr. Scheller has served as an adjunct professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco. Dr. Scheller's research elucidating the molecular machinery and regulatory mechanism that underly neurotransmitter release earned him the 2013 Albert Lasker Basic Medical Research Award, the 2010 Kavli Prize in Neuroscience, and the 1997 U.S. National Academy of Sciences Award in Molecular Biology. He is a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences, and a member of the National Academy of Medicine. Dr. Scheller holds a Ph.D. in Chemistry from the California Institute of Technology and B.Sc. in Biochemistry from the University of Wisconsin-Madison.
- Sharon Tetlow
-
Sharon Tetlow自2020年6月以来一直担任我们的监事会成员。她自2016年1月起创立并担任Potrero Hill Advisors（为生命科学公司提供战略和运营财务支持）的管理合伙人。在此之前，她曾于2013年至2016年1月担任Danforth Advisors（为生命科学公司提供服务的公司）的董事总经理，并于2011年至2013年担任生物技术公司Pathwork Diagnostics，Inc.的首席财务官。Tetlow女士自2020年1月起担任CatalystBiosciences，Inc.董事会成员。Tetlow女士在斯坦福大学（Stanford University）获得工商管理硕士学位，在特拉华大学（University of Delaware）获得心理学学士学位。
Sharon Tetlow has served on our board of directors since November 2020. Ms. Tetlow has served as Managing Partner of Potrero Hill Advisors, which provides strategic and operational financial support to life science companies through its team of chief financial officers and controllers since January 2016. She was previously a managing director with Danforth Advisors and before that served as chief financial officer of public and private biotechnology companies. She currently serves as board member, audit committee chair, and qualified financial expert for Catalyst Biosciences, Inc., a biopharmaceutical company, and serves on the supervisory board of directors and as audit committee chair of Valneva SE, a global, commercial stage, public vaccine company. She also serves on the board of the Altamont Pharma Special Acquisition Corp. Ms. Tetlow received her B.S. in Psychology from the University of Delaware and her M.B.A. from Stanford University. - Sharon Tetlow自2020年6月以来一直担任我们的监事会成员。她自2016年1月起创立并担任Potrero Hill Advisors（为生命科学公司提供战略和运营财务支持）的管理合伙人。在此之前，她曾于2013年至2016年1月担任Danforth Advisors（为生命科学公司提供服务的公司）的董事总经理，并于2011年至2013年担任生物技术公司Pathwork Diagnostics，Inc.的首席财务官。Tetlow女士自2020年1月起担任CatalystBiosciences，Inc.董事会成员。Tetlow女士在斯坦福大学（Stanford University）获得工商管理硕士学位，在特拉华大学（University of Delaware）获得心理学学士学位。
- Sharon Tetlow has served on our board of directors since November 2020. Ms. Tetlow has served as Managing Partner of Potrero Hill Advisors, which provides strategic and operational financial support to life science companies through its team of chief financial officers and controllers since January 2016. She was previously a managing director with Danforth Advisors and before that served as chief financial officer of public and private biotechnology companies. She currently serves as board member, audit committee chair, and qualified financial expert for Catalyst Biosciences, Inc., a biopharmaceutical company, and serves on the supervisory board of directors and as audit committee chair of Valneva SE, a global, commercial stage, public vaccine company. She also serves on the board of the Altamont Pharma Special Acquisition Corp. Ms. Tetlow received her B.S. in Psychology from the University of Delaware and her M.B.A. from Stanford University.
- Shaan C. Gandhi
-
Shaan C.Gandhi自2020年5月起担任我们的董事会成员。甘地博士是Northpond Ventures，LLC“；Northpond Ventures”；的董事，该公司是一家专注于科学、医疗和技术的风险投资公司，在那里他领导公司在生物技术方面的工作。此前，他曾担任Longwood Fund的负责人（从2018年到2020年），在那里他创建并投资了生命科学公司，包括Pyxis Oncology，这是一家癌症免疫疗法公司，专注于肿瘤微环境的新型调节剂，他联合创立并担任总裁。2018年至2019年，他是马萨诸塞州总医院的主治医师，2015年至2018年，他还在该医院做内科住院医师。他任职于各种私人公司的董事会，包括ARO Biotherapeutics，Camp4Therapeutics，Dice Molecules，StrideBio，Triumvira Immunologics和Vigil Neuroscience。他拥有哈佛医学院的硕士学位；哈佛商学院的工商管理硕士学位，在那里他是贝克学者；D.Phil。他是牛津大学的医学肿瘤学教授，在那里他是罗德学者；在凯斯西储大学（Case Western Reserve University）获得生物化学学士学位。
Shaan C. Gandhi has served on our board of directors since July 2020. Dr. Gandhi is a Director at Northpond Ventures, LLC, a global science, medical and technology-focused venture capital firm, where he leads the firm’s work in biotechnologies. Previously, Dr. Gandhi was a Principal at the Longwood Fund from 2018 to 2020 where he created and invested in life sciences companies, including Pyxis Oncology, a cancer immunotherapy company focused on novel modulators of the tumor microenvironment, which he co-founded and served as President. He was an attending hospitalist at Massachusetts General Hospital from 2018 to 2019 where he also did his residency in internal medicine from 2015 to 2018. He serves on the boards of directors of various private companies, including Aro Biotherapeutics, CAMP4 Therapeutics, Candel Therapeutics, StrideBio, Triumvira Immunologics and Vigil Neuroscience. He holds an M.D. from Harvard Medical School; an M.B.A. from Harvard Business School, where he was a Baker Scholar; a D.Phil. in medical oncology from the University of Oxford, where he was a Rhodes Scholar; and a B.S. with honors in biochemistry from Case Western Reserve University. - Shaan C.Gandhi自2020年5月起担任我们的董事会成员。甘地博士是Northpond Ventures，LLC“；Northpond Ventures”；的董事，该公司是一家专注于科学、医疗和技术的风险投资公司，在那里他领导公司在生物技术方面的工作。此前，他曾担任Longwood Fund的负责人（从2018年到2020年），在那里他创建并投资了生命科学公司，包括Pyxis Oncology，这是一家癌症免疫疗法公司，专注于肿瘤微环境的新型调节剂，他联合创立并担任总裁。2018年至2019年，他是马萨诸塞州总医院的主治医师，2015年至2018年，他还在该医院做内科住院医师。他任职于各种私人公司的董事会，包括ARO Biotherapeutics，Camp4Therapeutics，Dice Molecules，StrideBio，Triumvira Immunologics和Vigil Neuroscience。他拥有哈佛医学院的硕士学位；哈佛商学院的工商管理硕士学位，在那里他是贝克学者；D.Phil。他是牛津大学的医学肿瘤学教授，在那里他是罗德学者；在凯斯西储大学（Case Western Reserve University）获得生物化学学士学位。
- Shaan C. Gandhi has served on our board of directors since July 2020. Dr. Gandhi is a Director at Northpond Ventures, LLC, a global science, medical and technology-focused venture capital firm, where he leads the firm’s work in biotechnologies. Previously, Dr. Gandhi was a Principal at the Longwood Fund from 2018 to 2020 where he created and invested in life sciences companies, including Pyxis Oncology, a cancer immunotherapy company focused on novel modulators of the tumor microenvironment, which he co-founded and served as President. He was an attending hospitalist at Massachusetts General Hospital from 2018 to 2019 where he also did his residency in internal medicine from 2015 to 2018. He serves on the boards of directors of various private companies, including Aro Biotherapeutics, CAMP4 Therapeutics, Candel Therapeutics, StrideBio, Triumvira Immunologics and Vigil Neuroscience. He holds an M.D. from Harvard Medical School; an M.B.A. from Harvard Business School, where he was a Baker Scholar; a D.Phil. in medical oncology from the University of Oxford, where he was a Rhodes Scholar; and a B.S. with honors in biochemistry from Case Western Reserve University.
- Jake Simson
-
Jake Simson，自2023年6月起担任Septerna，Inc.董事会成员。自2020年12月以来，Simson博士一直担任多阶段生命科学投资公司RA Capital的合伙人。2013年7月至2020年12月，Simson博士在RA Capital担任助理、分析师，随后担任负责人。Simson博士目前在上市的生物制药公司Bicara Therapeutics Inc.（纳斯达克：BCAX）的董事会、上市的免疫治疗公司Janux Therapeutics, Inc.（纳斯达克：JANX）和上市的精准医疗公司Tyra Biosciences, Inc.，Inc.（纳斯达克：TYRA）的董事会任职，还在多家私营生物技术公司的董事会任职。Simson博士此前曾在DICE Therapeutics, Inc.（纳斯达克：DICE）的董事会任职，DICE Therapeutics, Inc.是一家上市的生物制药公司，任职于2020年12月至2023年8月期间，DICE Therapeutics, Inc.被礼来公司收购。Simson博士在麻省理工学院获得材料科学与工程学士学位，在约翰斯·霍普金斯大学获得生物医学工程博士学位。
Jake Simson,has served as a member of Board of Directors since March 2021. Dr. Simson has served as a Partner at RA Capital Management, L.P. ("RA Capital") since December 2020. Previously, Dr. Simson served as an associate, analyst and principal at RA Capital from July 2013 to December 2020. Dr. Simson also serves as a member of the board of directors of Tyra Biosciences, a public biotechnology company, and each of Bicara Therapeutics, Convergent Therapeutics and Septerna, each a private biotechnology company. Dr. Simson received an S.B. in Materials Science and Engineering from the Massachusetts Institute of Technology and a Ph.D. in Biomedical Engineering from the Johns Hopkins University. - Jake Simson，自2023年6月起担任Septerna，Inc.董事会成员。自2020年12月以来，Simson博士一直担任多阶段生命科学投资公司RA Capital的合伙人。2013年7月至2020年12月，Simson博士在RA Capital担任助理、分析师，随后担任负责人。Simson博士目前在上市的生物制药公司Bicara Therapeutics Inc.（纳斯达克：BCAX）的董事会、上市的免疫治疗公司Janux Therapeutics, Inc.（纳斯达克：JANX）和上市的精准医疗公司Tyra Biosciences, Inc.，Inc.（纳斯达克：TYRA）的董事会任职，还在多家私营生物技术公司的董事会任职。Simson博士此前曾在DICE Therapeutics, Inc.（纳斯达克：DICE）的董事会任职，DICE Therapeutics, Inc.是一家上市的生物制药公司，任职于2020年12月至2023年8月期间，DICE Therapeutics, Inc.被礼来公司收购。Simson博士在麻省理工学院获得材料科学与工程学士学位，在约翰斯·霍普金斯大学获得生物医学工程博士学位。
- Jake Simson,has served as a member of Board of Directors since March 2021. Dr. Simson has served as a Partner at RA Capital Management, L.P. ("RA Capital") since December 2020. Previously, Dr. Simson served as an associate, analyst and principal at RA Capital from July 2013 to December 2020. Dr. Simson also serves as a member of the board of directors of Tyra Biosciences, a public biotechnology company, and each of Bicara Therapeutics, Convergent Therapeutics and Septerna, each a private biotechnology company. Dr. Simson received an S.B. in Materials Science and Engineering from the Massachusetts Institute of Technology and a Ph.D. in Biomedical Engineering from the Johns Hopkins University.
- Jim Scopa
-
Jim Scopa自2020年11月以来一直在我们的董事会任职。Scopa先生自2017年7月起担任澳大利亚风险投资公司Oneventures的顾问委员会和投资咨询委员会成员。2017年1月至2018年6月，Scopa先生是斯坦福大学杰出职业研究所的研究员。从2005年5月到2017年6月，他曾任职于生命科学风险投资公司MPM Capital的投资委员会。Scopa先生在哈佛学院获得了学士学位，在哈佛商学院获得了工商管理硕士学位，在哈佛法学院获得了法学博士学位。
Jim Scopa has served on our board of directors since November 2020. Mr. Scopa has served as a member of the advisory board and the investment advisory committee of OneVentures, an Australian venture capital firm since July 2017. From January 2017 to June 2018 Mr. Scopa was a fellow at Stanford University in the Distinguished Careers Institute. From May 2005 to June 2017 he served on the investment committee of MPM Capital, a life sciences venture capital firm. Mr. Scopa received his A.B. from Harvard College, his M.B.A. from Harvard Business School, and his J.D. from Harvard Law School. - Jim Scopa自2020年11月以来一直在我们的董事会任职。Scopa先生自2017年7月起担任澳大利亚风险投资公司Oneventures的顾问委员会和投资咨询委员会成员。2017年1月至2018年6月，Scopa先生是斯坦福大学杰出职业研究所的研究员。从2005年5月到2017年6月，他曾任职于生命科学风险投资公司MPM Capital的投资委员会。Scopa先生在哈佛学院获得了学士学位，在哈佛商学院获得了工商管理硕士学位，在哈佛法学院获得了法学博士学位。
- Jim Scopa has served on our board of directors since November 2020. Mr. Scopa has served as a member of the advisory board and the investment advisory committee of OneVentures, an Australian venture capital firm since July 2017. From January 2017 to June 2018 Mr. Scopa was a fellow at Stanford University in the Distinguished Careers Institute. From May 2005 to June 2017 he served on the investment committee of MPM Capital, a life sciences venture capital firm. Mr. Scopa received his A.B. from Harvard College, his M.B.A. from Harvard Business School, and his J.D. from Harvard Law School.
- Stephen Zachary
-
Stephen Zachary自2018年7月起担任我们的董事会成员。Zachary博士于2016年加入Sands Capital，自2018年7月起担任Sands Capital合伙人。从2017年7月到2018年8月，Zachary博士还担任Agilis Biotherapeutics，Inc.的研究分析总监，该公司是一家基因疗法公司，被PtcTherapeutics，Inc.收购Zachary博士在华盛顿和李大学获得哲学学士学位，在约翰霍普金斯医学院获得神经科学博士学位。他是考夫曼奖学金23班的成员。
Stephen Zachary has served on our board of directors since July 2018. Dr. Zachary joined Sands Capital in 2016 and has served as a Partner at Sands Capital since July 2018. From July 2017 to August 2018 Dr. Zachary also served as the Director of Research Analytics at Agilis Biotherapeutics, Inc., a gene therapy company that was acquired by PTC Therapeutics, Inc. Dr. Zachary received his B.A. in Philosophy from Washington & Lee University and his Ph.D. in Neuroscience from Johns Hopkins School of Medicine. He is a member of the Kauffman Fellowship Class 23. - Stephen Zachary自2018年7月起担任我们的董事会成员。Zachary博士于2016年加入Sands Capital，自2018年7月起担任Sands Capital合伙人。从2017年7月到2018年8月，Zachary博士还担任Agilis Biotherapeutics，Inc.的研究分析总监，该公司是一家基因疗法公司，被PtcTherapeutics，Inc.收购Zachary博士在华盛顿和李大学获得哲学学士学位，在约翰霍普金斯医学院获得神经科学博士学位。他是考夫曼奖学金23班的成员。
- Stephen Zachary has served on our board of directors since July 2018. Dr. Zachary joined Sands Capital in 2016 and has served as a Partner at Sands Capital since July 2018. From July 2017 to August 2018 Dr. Zachary also served as the Director of Research Analytics at Agilis Biotherapeutics, Inc., a gene therapy company that was acquired by PTC Therapeutics, Inc. Dr. Zachary received his B.A. in Philosophy from Washington & Lee University and his Ph.D. in Neuroscience from Johns Hopkins School of Medicine. He is a member of the Kauffman Fellowship Class 23.
- J. Kevin Judice
-
J.Kevin Judice是我们的联合创始人之一，自2013年8月起担任我们的首席执行官。从2012年12月到2015年1月，Judice博士担任CidaraTherapeutics，Inc.的首席科学官，这是一家他共同创立的生物技术公司。从2004年5月到2011年10月，Judice博士担任Achaogen，Inc.（他创立的上市生物制药公司）的首席科学官和首席执行官。从2002年4月到2003年5月，Judice博士担任Genentech，Inc.（一家生物制药公司，现在是罗氏集团的一部分）药物化学高级总监。从1997年9月到2002年3月，他担任TheravanceBiopharma，Inc.的化学副总裁。从1993年8月到1997年8月，Judice博士担任Genentech，Inc.生物有机化学的科学家朱迪斯博士在德克萨斯农工大学获得化学学士学位，在加州大学洛杉矶分校获得有机化学博士学位，并在加州大学伯克利分校获得博士后奖学金。
J. Kevin Judice is one of our co-founders and has served as our Chief Executive Officer since August 2013. From December 2012 to January 2015 Dr. Judice served as the Chief Scientific Officer of Cidara Therapeutics, Inc., a biotechnology company that he co-founded. From May 2004 to October 2011 Dr. Judice served as the Chief Scientific Officer and Chief Executive Officer of Achaogen, Inc., a publicly traded biopharmaceutical company he founded. From April 2002 to May 2003 Dr. Judice served as Senior Director, Medicinal Chemistry at Genentech, Inc., a biopharmaceutical company that is now part of the Roche Group. From September 1997 to March 2002 he served as Vice President, Chemistry at Theravance Biopharma, Inc. From August 1993 to August 1997 Dr. Judice served as Scientist, Bioorganic Chemistry at Genentech, Inc. Dr. Judice received his B.S. in Chemistry from Texas A&M University, his Ph.D. in Organic Chemistry from the University of California, Los Angeles completed a postdoctoral fellowship at the University of California, Berkeley. - J.Kevin Judice是我们的联合创始人之一，自2013年8月起担任我们的首席执行官。从2012年12月到2015年1月，Judice博士担任CidaraTherapeutics，Inc.的首席科学官，这是一家他共同创立的生物技术公司。从2004年5月到2011年10月，Judice博士担任Achaogen，Inc.（他创立的上市生物制药公司）的首席科学官和首席执行官。从2002年4月到2003年5月，Judice博士担任Genentech，Inc.（一家生物制药公司，现在是罗氏集团的一部分）药物化学高级总监。从1997年9月到2002年3月，他担任TheravanceBiopharma，Inc.的化学副总裁。从1993年8月到1997年8月，Judice博士担任Genentech，Inc.生物有机化学的科学家朱迪斯博士在德克萨斯农工大学获得化学学士学位，在加州大学洛杉矶分校获得有机化学博士学位，并在加州大学伯克利分校获得博士后奖学金。
- J. Kevin Judice is one of our co-founders and has served as our Chief Executive Officer since August 2013. From December 2012 to January 2015 Dr. Judice served as the Chief Scientific Officer of Cidara Therapeutics, Inc., a biotechnology company that he co-founded. From May 2004 to October 2011 Dr. Judice served as the Chief Scientific Officer and Chief Executive Officer of Achaogen, Inc., a publicly traded biopharmaceutical company he founded. From April 2002 to May 2003 Dr. Judice served as Senior Director, Medicinal Chemistry at Genentech, Inc., a biopharmaceutical company that is now part of the Roche Group. From September 1997 to March 2002 he served as Vice President, Chemistry at Theravance Biopharma, Inc. From August 1993 to August 1997 Dr. Judice served as Scientist, Bioorganic Chemistry at Genentech, Inc. Dr. Judice received his B.S. in Chemistry from Texas A&M University, his Ph.D. in Organic Chemistry from the University of California, Los Angeles completed a postdoctoral fellowship at the University of California, Berkeley.
- Sharon Tetlow
-
Sharon Tetlow，自2022年3月起担任Structure Therapeutics公司董事会成员。自2016年1月以来，Tetlow女士担任Potrero Hill Advisors的管理合伙人，该公司是一家向生命科学公司提供战略和运营财务支持的咨询公司。在加入Potrero Hill Advisors之前，Tetlow女士在过去20年里担任过几家公共和私营生物技术公司的首席财务官。Tetlow女士目前在生物制药公司DICE Therapeutics, Inc.（Nasdaq：DICE）的董事会、提名和治理委员会以及审计委员会主席、生物制药公司Catalyst Biosciences, Inc.（Nasdaq：CBIO）的董事会以及审计委员会主席、Valneva SE（Nasdaq：VALN，EPA：VLA）的监事会以及审计委员会主席，Valneva SE是一家全球商业上市疫苗公司。Tetlow女士在特拉华大学获得心理学学士学位，在斯坦福大学获得工商管理硕士学位。
Sharon Tetlow,has served as a member of Structure Therapeutics Inc. board of directors since March 2022. Since January 2016, Ms. Tetlow has served as Managing Partner of Potrero Hill Advisors, an advisory firm providing strategic and operational financial support to life sciences companies. Prior to Potrero Hill Advisors, Ms. Tetlow served as chief financial officer of several public and private biotech companies for the previous twenty years. Ms. Tetlow currently serves on the board of directors, on the nominating and governance committee and as chair of the audit committee of DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company, on the board of directors and as chair of the audit committee of Catalyst Biosciences, Inc. (Nasdaq: CBIO), a biopharmaceutical company, and on the supervisory board and as chair of the audit committee of Valneva SE (Nasdaq: VALN, EPA: VLA), a global commercial stage, public vaccine company. Ms. Tetlow received her B.S. in Psychology from the University of Delaware and her M.B.A. from Stanford University. - Sharon Tetlow，自2022年3月起担任Structure Therapeutics公司董事会成员。自2016年1月以来，Tetlow女士担任Potrero Hill Advisors的管理合伙人，该公司是一家向生命科学公司提供战略和运营财务支持的咨询公司。在加入Potrero Hill Advisors之前，Tetlow女士在过去20年里担任过几家公共和私营生物技术公司的首席财务官。Tetlow女士目前在生物制药公司DICE Therapeutics, Inc.（Nasdaq：DICE）的董事会、提名和治理委员会以及审计委员会主席、生物制药公司Catalyst Biosciences, Inc.（Nasdaq：CBIO）的董事会以及审计委员会主席、Valneva SE（Nasdaq：VALN，EPA：VLA）的监事会以及审计委员会主席，Valneva SE是一家全球商业上市疫苗公司。Tetlow女士在特拉华大学获得心理学学士学位，在斯坦福大学获得工商管理硕士学位。
- Sharon Tetlow,has served as a member of Structure Therapeutics Inc. board of directors since March 2022. Since January 2016, Ms. Tetlow has served as Managing Partner of Potrero Hill Advisors, an advisory firm providing strategic and operational financial support to life sciences companies. Prior to Potrero Hill Advisors, Ms. Tetlow served as chief financial officer of several public and private biotech companies for the previous twenty years. Ms. Tetlow currently serves on the board of directors, on the nominating and governance committee and as chair of the audit committee of DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company, on the board of directors and as chair of the audit committee of Catalyst Biosciences, Inc. (Nasdaq: CBIO), a biopharmaceutical company, and on the supervisory board and as chair of the audit committee of Valneva SE (Nasdaq: VALN, EPA: VLA), a global commercial stage, public vaccine company. Ms. Tetlow received her B.S. in Psychology from the University of Delaware and her M.B.A. from Stanford University.
高管简历
中英对照 | 中文 | 英文- J. Kevin Judice
J.Kevin Judice是我们的联合创始人之一，自2013年8月起担任我们的首席执行官。从2012年12月到2015年1月，Judice博士担任CidaraTherapeutics，Inc.的首席科学官，这是一家他共同创立的生物技术公司。从2004年5月到2011年10月，Judice博士担任Achaogen，Inc.（他创立的上市生物制药公司）的首席科学官和首席执行官。从2002年4月到2003年5月，Judice博士担任Genentech，Inc.（一家生物制药公司，现在是罗氏集团的一部分）药物化学高级总监。从1997年9月到2002年3月，他担任TheravanceBiopharma，Inc.的化学副总裁。从1993年8月到1997年8月，Judice博士担任Genentech，Inc.生物有机化学的科学家朱迪斯博士在德克萨斯农工大学获得化学学士学位，在加州大学洛杉矶分校获得有机化学博士学位，并在加州大学伯克利分校获得博士后奖学金。
J. Kevin Judice is one of our co-founders and has served as our Chief Executive Officer since August 2013. From December 2012 to January 2015 Dr. Judice served as the Chief Scientific Officer of Cidara Therapeutics, Inc., a biotechnology company that he co-founded. From May 2004 to October 2011 Dr. Judice served as the Chief Scientific Officer and Chief Executive Officer of Achaogen, Inc., a publicly traded biopharmaceutical company he founded. From April 2002 to May 2003 Dr. Judice served as Senior Director, Medicinal Chemistry at Genentech, Inc., a biopharmaceutical company that is now part of the Roche Group. From September 1997 to March 2002 he served as Vice President, Chemistry at Theravance Biopharma, Inc. From August 1993 to August 1997 Dr. Judice served as Scientist, Bioorganic Chemistry at Genentech, Inc. Dr. Judice received his B.S. in Chemistry from Texas A&M University, his Ph.D. in Organic Chemistry from the University of California, Los Angeles completed a postdoctoral fellowship at the University of California, Berkeley.- J.Kevin Judice是我们的联合创始人之一，自2013年8月起担任我们的首席执行官。从2012年12月到2015年1月，Judice博士担任CidaraTherapeutics，Inc.的首席科学官，这是一家他共同创立的生物技术公司。从2004年5月到2011年10月，Judice博士担任Achaogen，Inc.（他创立的上市生物制药公司）的首席科学官和首席执行官。从2002年4月到2003年5月，Judice博士担任Genentech，Inc.（一家生物制药公司，现在是罗氏集团的一部分）药物化学高级总监。从1997年9月到2002年3月，他担任TheravanceBiopharma，Inc.的化学副总裁。从1993年8月到1997年8月，Judice博士担任Genentech，Inc.生物有机化学的科学家朱迪斯博士在德克萨斯农工大学获得化学学士学位，在加州大学洛杉矶分校获得有机化学博士学位，并在加州大学伯克利分校获得博士后奖学金。
- J. Kevin Judice is one of our co-founders and has served as our Chief Executive Officer since August 2013. From December 2012 to January 2015 Dr. Judice served as the Chief Scientific Officer of Cidara Therapeutics, Inc., a biotechnology company that he co-founded. From May 2004 to October 2011 Dr. Judice served as the Chief Scientific Officer and Chief Executive Officer of Achaogen, Inc., a publicly traded biopharmaceutical company he founded. From April 2002 to May 2003 Dr. Judice served as Senior Director, Medicinal Chemistry at Genentech, Inc., a biopharmaceutical company that is now part of the Roche Group. From September 1997 to March 2002 he served as Vice President, Chemistry at Theravance Biopharma, Inc. From August 1993 to August 1997 Dr. Judice served as Scientist, Bioorganic Chemistry at Genentech, Inc. Dr. Judice received his B.S. in Chemistry from Texas A&M University, his Ph.D. in Organic Chemistry from the University of California, Los Angeles completed a postdoctoral fellowship at the University of California, Berkeley.
- John Jacobsen
John Jacobsen自2021年6月起担任我们的首席科学官，此前从2019年9月到2021年6月担任我们的药物发现高级副总裁，从2015年11月到2019年9月担任我们的化学高级副总裁。加入我们之前，从1998年6月到2015年10月，Jacobsen博士担任Theravance Biopharma（生物制药公司）的多种职务，最近担任药物化学高级总监。雅各布森博士在哈佛大学获得化学学士学位，在加州大学伯克利分校获得有机化学博士学位。
John Jacobsen has served as our Chief Scientific Officer since June 2021 and has previously served as our Senior Vice President, Drug Discovery from September 2019 to June 2021 and our Senior Vice President, Chemistry from November 2015 to September 2019. Prior to joining us, from June 1998 to October 2015 Dr. Jacobsen served in various capacities at Theravance Biopharma, a biopharmaceutical company, most recently as Senior Director of Medicinal Chemistry. Dr. Jacobsen received his A.B. in Chemistry from Harvard College and his Ph.D. in Organic Chemistry from the University of California, Berkeley.- John Jacobsen自2021年6月起担任我们的首席科学官，此前从2019年9月到2021年6月担任我们的药物发现高级副总裁，从2015年11月到2019年9月担任我们的化学高级副总裁。加入我们之前，从1998年6月到2015年10月，Jacobsen博士担任Theravance Biopharma（生物制药公司）的多种职务，最近担任药物化学高级总监。雅各布森博士在哈佛大学获得化学学士学位，在加州大学伯克利分校获得有机化学博士学位。
- John Jacobsen has served as our Chief Scientific Officer since June 2021 and has previously served as our Senior Vice President, Drug Discovery from September 2019 to June 2021 and our Senior Vice President, Chemistry from November 2015 to September 2019. Prior to joining us, from June 1998 to October 2015 Dr. Jacobsen served in various capacities at Theravance Biopharma, a biopharmaceutical company, most recently as Senior Director of Medicinal Chemistry. Dr. Jacobsen received his A.B. in Chemistry from Harvard College and his Ph.D. in Organic Chemistry from the University of California, Berkeley.
- Timothy Lu
Timothy Lu自2020年8月起担任我们的首席医疗官。在加入我们之前，从2012年10月到2020年8月，Lu博士在临床开发中担任越来越多的领导职务，包括担任Genentech，Inc.（生物制药公司，现为Roche Group的一部分）IBD的治疗领域负责人。在加入Genentech之前，Lu博士完成了他的内科培训和胃肠病学奖学金，并担任加州大学旧金山分校胃肠病学系的医学助理教授。卢医生是一名董事会认证的胃肠科医生。Lu博士在耶鲁大学获得生物学学士学位，在德克萨斯大学西南医学中心获得医学博士学位。
Timothy Lu has served as our Chief Medical Officer since August 2020. Prior to joining us, from October 2012 to August 2020 Dr. Lu held increasing leadership roles in clinical development including serving as the Therapeutic Area Lead for IBD at Genentech, Inc., a biopharmaceutical company that is now part of the Roche Group. Prior to Genentech, Dr. Lu completed his internal medicine training and gastroenterology fellowship at and was an Assistant Professor of Medicine in the Department of Gastroenterology at the University of California San Francisco. Dr. Lu is a board-certified Gastroenterologist. Dr. Lu received B.S. in Biology from Yale University and his M.D., Ph.D. degree from the University of Texas Southwestern Medical Center.- Timothy Lu自2020年8月起担任我们的首席医疗官。在加入我们之前，从2012年10月到2020年8月，Lu博士在临床开发中担任越来越多的领导职务，包括担任Genentech，Inc.（生物制药公司，现为Roche Group的一部分）IBD的治疗领域负责人。在加入Genentech之前，Lu博士完成了他的内科培训和胃肠病学奖学金，并担任加州大学旧金山分校胃肠病学系的医学助理教授。卢医生是一名董事会认证的胃肠科医生。Lu博士在耶鲁大学获得生物学学士学位，在德克萨斯大学西南医学中心获得医学博士学位。
- Timothy Lu has served as our Chief Medical Officer since August 2020. Prior to joining us, from October 2012 to August 2020 Dr. Lu held increasing leadership roles in clinical development including serving as the Therapeutic Area Lead for IBD at Genentech, Inc., a biopharmaceutical company that is now part of the Roche Group. Prior to Genentech, Dr. Lu completed his internal medicine training and gastroenterology fellowship at and was an Assistant Professor of Medicine in the Department of Gastroenterology at the University of California San Francisco. Dr. Lu is a board-certified Gastroenterologist. Dr. Lu received B.S. in Biology from Yale University and his M.D., Ph.D. degree from the University of Texas Southwestern Medical Center.
- Scott Robertson
Scott Robertson自2017年12月起担任我们的首席财务官，自2021年7月起担任我们的首席商务官，此前于2016年4月至2017年12月担任我们的业务发展副总裁。在加入我们之前，2010年3月至2016年4月，Robertson先生担任Dupont Pioneer的业务发展总监，负责并购和战略合作。从2006年8月到2010年3月，Robertson先生是MPM Capital的投资专家，这是一家专注于生命科学的风险投资基金。从2005年到2006年，Robertson先生是Merrill Lynch&Co.医疗保健投资银行团队的成员。此外，他目前担任加州大学伯克利分校哈斯商学院（Haas School of Business）的讲师，以及生物技术公司Hexima Limited的董事会成员。Robertson先生在南加州大学获得工商管理学士学位，在加州大学伯克利分校哈斯商学院获得工商管理硕士学位。
Scott Robertson,has served as a member of Bicara Therapeutics Inc. board of directors since September 2023. Mr. Robertson currently serves as the Chief Financial Officer and Chief Business Officer of Star Therapeutics LLC, a biotechnology company, since January 2024. Mr. Robertson also served as the Chief Financial Officer and Chief Business Officer of DICE from July 2021 to December 2023, the Chief Financial Officer from December 2017 to July 2021, and as the Vice President, Business Development & Strategic Planning from April 2016 to December 2017, prior to acquisition by Eli Lilly and Company in August 2023. In addition, he currently serves as a Lecturer at the Haas School of Business at the University of California, Berkeley and previously served as a member of the board of directors of Hexima Limited (ASX:HXL), a biotechnology company, from December 2018 to September 2023. Mr. Robertson received his B.S. in Business Administration from the University of Southern California and his M.B.A. from the Haas School of Business at the University of California, Berkeley.- Scott Robertson自2017年12月起担任我们的首席财务官，自2021年7月起担任我们的首席商务官，此前于2016年4月至2017年12月担任我们的业务发展副总裁。在加入我们之前，2010年3月至2016年4月，Robertson先生担任Dupont Pioneer的业务发展总监，负责并购和战略合作。从2006年8月到2010年3月，Robertson先生是MPM Capital的投资专家，这是一家专注于生命科学的风险投资基金。从2005年到2006年，Robertson先生是Merrill Lynch&Co.医疗保健投资银行团队的成员。此外，他目前担任加州大学伯克利分校哈斯商学院（Haas School of Business）的讲师，以及生物技术公司Hexima Limited的董事会成员。Robertson先生在南加州大学获得工商管理学士学位，在加州大学伯克利分校哈斯商学院获得工商管理硕士学位。
- Scott Robertson,has served as a member of Bicara Therapeutics Inc. board of directors since September 2023. Mr. Robertson currently serves as the Chief Financial Officer and Chief Business Officer of Star Therapeutics LLC, a biotechnology company, since January 2024. Mr. Robertson also served as the Chief Financial Officer and Chief Business Officer of DICE from July 2021 to December 2023, the Chief Financial Officer from December 2017 to July 2021, and as the Vice President, Business Development & Strategic Planning from April 2016 to December 2017, prior to acquisition by Eli Lilly and Company in August 2023. In addition, he currently serves as a Lecturer at the Haas School of Business at the University of California, Berkeley and previously served as a member of the board of directors of Hexima Limited (ASX:HXL), a biotechnology company, from December 2018 to September 2023. Mr. Robertson received his B.S. in Business Administration from the University of Southern California and his M.B.A. from the Haas School of Business at the University of California, Berkeley.